



Universidad de Valladolid



**INNOVACION**  
OTRI UVA  
OFICINA PROYECTOS  
EUROPEOS  
UNIDAD DE PATENTES

## Publicación de las últimas convocatorias del VIIPM

Hoy, 10 de julio de 2012, se publicará el último paquete de convocatorias del 7º Programa Marco, con un presupuesto total de 8.100 M€

Serán las convocatorias ***con mayor presupuesto del 7PM***, iniciado en 2007.

Las áreas temáticas contarán con 4.800 M€ el ERC 1.700 M€ y People 963 M€ Destaca especialmente el dinero reservado para la participación de PYMES, un total de 1.200 M€

### FP7-HEALTH-2013

CALL	TÍTULO	Fecha de publicación	Fecha límite	Presupuesto		Tamaño consorcio	Duración	Observaciones
<a href="#">INNOVATION-2</a>  2 TOPICS	P7-HEALTH-2013-SMES-FOR-INNOVATION	2012-07-10	2012-09-25	€ 140 000 000	Short proposal: max. 6 pages in the 1st stage	3-5	3 años	<ul style="list-style-type: none"> <li>Importancia a las cuestiones éticas, pacientes y estadística</li> <li>min. 50% presupuesto PYMES (EU o países asociados)</li> </ul>

CALL	TÍTULO	Fecha de publicación	Fecha límite	Presupuesto	
<a href="#">INNOVATION-1</a>  34 TOPICS	FP7-HEALTH-2013-INNOVATION	2012-07-10	2012-10-02	€ 679 300 000	Short proposal: max. 6 pages in the 1st stage



Universidad de Valladolid



**INNOVACION**  
OTRI UVA  
OFICINA PROYECTOS  
EUROPEOS  
UNIDAD DE PATENTES

## CARACTERÍSTICAS GENERALES 2013

PARTICIPANTES	Niveles financiación	
Todo organismo de investigación	75% Costes de investigación	100% de gastos gestión y formación y Propiedad intelectual
PYMES	75% Costes de investigación	
GRANDES EMPRESAS	50% Costes de investigación	
EMPRESAS proveedores de servicios.	Depende tamaño empresa	

## Convocatorias TOPICS

### [FP7-HEALTH-2013- INNOVATION-2](#)

INNOVATION-2	
HEALTH.2013.0-1,	Boosting the translation of health research projects' results into innovative applications for health.
HEALTH.2013.2.3.1-1	Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance



Universidad de Valladolid



**INNOVACION**  
OTRI UVA  
OFICINA PROYECTOS  
EUROPEOS  
UNIDAD DE PATENTES

[Convocatorias TOPICS FP7-HEALTH-2013- INNOVATION-1](#)

<b>INNOVATION-1</b>	
<b>HEALTH.2013.1.2-1,</b>	Development of imaging technologies for therapeutic interventions in rare diseases.
<b>HEALTH.2013.1.3-1,</b>	Modelling toxic responses in case studies for predictive human safety assessment.
<b>HEALTH.2013.1.3-2,</b>	Innovative approaches to address adverse immune reactions to biomedical devices, implants and transplant tissues
<b>HEALTH.2013.1.3-3,</b>	Safety and efficacy of therapeutic vaccines
<b>HEALTH.2013.1.3-4,</b>	Development of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines
<b>HEALTH.2013.1.4-1,</b>	Controlling differentiation and proliferation in human stem cells intended for therapeutic use
<b>HEALTH.2013.2.1.1-1,</b>	Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes
<b>HEALTH.2013.2.1.1-2,</b>	High impact research initiative on metagenomics for personalised medicine approaches.
<b>HEALTH.2013.2.2.1-1,</b>	Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI).
<b>HEALTH.2013.2.2.1-2,</b>	Development of effective imaging tools for diagnosis, monitoring and management of mental disorders <sup>37</sup>
<b>HEALTH.2013.2.2.1-3,</b>	Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment.
<b>HEALTH.2013.2.2.1-4,</b>	Patho-physiology and therapy of epilepsy and epileptiform disorders
<b>HEALTH.2013.2.2.1-5,</b>	Understanding and controlling pain.
<b>HEALTH.2013.2.3.0-1,</b>	Innovation in vaccines.
<b>HEALTH.2013.2.3.1-2,</b>	stratified approaches to antibacterial and/or antifungal treatment.
<b>HEALTH.2013.2.3.3-1,</b>	Clinical management of patients in severe epidemics



Universidad de Valladolid



**INNOVACION**  
OTRI UVA  
OFICINA PROYECTOS  
EUROPEOS  
UNIDAD DE PATENTES

<b>INNOVATION-1</b>	
<b>HEALTH.2013.2.3.4-1,</b>	Neglected infectious diseases of Central and Eastern Europe
<b>HEALTH.2013.2.3.4-2,</b>	Drug development for neglected parasitic diseases.
<b>HEALTH.2013.2.4.1-1,</b>	Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer
<b>HEALTH.2013.2.4.1-2,</b>	Strengthening the cancer patient's immune system
<b>HEALTH.2013.2.4.1-3,</b>	Investigator-driven supportive and palliative care clinical trials and observational studies.
<b>HEALTH.2013.2.4.2-1,</b>	Discovery research to reveal novel targets for cardiovascular disease treatment.
<b>HEALTH.2013.2.4.2-2,</b>	Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases.
<b>HEALTH.2013.2.4.2-3,</b>	Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan
<b>HEALTH.2013.3.1-1,</b>	Comparative effectiveness research (CER) in health systems and health services interventions.
<b>HEALTH.2013.3.3-1,</b>	Social innovation <sup>42</sup> for health promotion
<b>HEALTH.2013.4.1-1</b>	Supporting industrial participation in EU-funded research in the Health sector.
<b>HEALTH.2013.4.1-2,</b>	Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation.
<b>HEALTH.2013.4.1-3,</b>	Support for Presidency events: Organisation of supporting actions and events associated to the Presidency of the European Union.
<b>HEALTH.2013.4.1-4,</b>	Preparing the future for health research and innovation
<b>HEALTH.2013.4.1-5,</b>	Global initiative on gene-environment interactions in diabetes/obesity in specific populations
<b>HEALTH.2013.4.1-6,</b>	Mapping chronic non-communicable diseases research activities.
<b>HEALTH.2013.4.2-1,</b>	Investigator-driven clinical trials for off-patent medicines



Universidad de Valladolid



**INNOVACION**  
OTRI UVA  
OFICINA PROYECTOS  
EUROPEOS  
UNIDAD DE PATENTES

<b>INNOVATION-1</b>	
	using innovative, age-appropriate formulations and/or delivery systems
<b>HEALTH.2013.4.2-2,</b>	Adverse drug reaction research
<b>HEALTH.2013.4.2-3</b>	New methodologies for clinical trials for small population groups